论文部分内容阅读
[目的]通过临床观察探究中药灌肠方青赤散治疗溃疡性结肠炎临床疗效。[方法]将符合纳入标准41名患者随机分为2组,对照组为20例,治疗组为21例,对照组口服美沙拉嗪肠溶片治疗,治疗组在口服美沙拉嗪肠溶片基础上加用青赤散保留灌肠治疗,比较两组治疗前后主要临床症状及肠镜改变积分、疾病活动性总积分、临床疗效、C反应蛋白(CRP)及血沉(ESR)。[结果]1)与治疗前相比较,治疗后两组在腹痛、大便次数、便血、肠镜改变及疾病活动性方面均有明显改善(P<0.05),并且治疗组优于对照组(P<0.05)。2)在临床疗效方面,治疗组总有效率优于对照组(P<0.05)。3)在CRP、ESR方面,两组治疗后均较治疗前降低(P<0.05);与对照组比较,治疗组治疗后的CRP、ESR均低于对照组(P<0.05)。[结论]青赤散保留灌肠治疗溃疡性结肠炎具有较好疗效,临床值得推广。
[Objective] To investigate the curative effect of enema Fangqingchisan on ulcerative colitis through clinical observation. [Methods] Forty-one patients who met the inclusion criteria were randomly divided into two groups, the control group was 20 cases and the treatment group was 21 cases. The control group was treated with mesalazine enteric-coated tablets. The treatment group was given oral Mesalazine enteric-coated tablets The patients were divided into two groups. The main clinical symptoms, colonoscopy changes integral, disease activity total score, clinical curative effect, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were compared before and after treatment. [Results] 1) Compared with those before treatment, the two groups had significant improvement in abdominal pain, stool frequency, blood in the stool, colonoscopy and disease activity (P <0.05), and the treatment group was better than the control group <0.05). 2) In terms of clinical efficacy, the total effective rate of the treatment group was better than that of the control group (P <0.05). 3) Compared with the control group, the CRP and ESR of the treatment group were lower than those of the control group (P <0.05). [Conclusion] Qing Chuan San retention enema for the treatment of ulcerative colitis has a good effect, clinical worth promoting.